The U.S. Food and Drug Administration widened its warning about Diamond Shruumz edible products linked to illnesses across multiple states, with a nationwide recall underway. California-based...
Psychedelic drug company Lykos Therapeutics wasn’t too happy with the Final Evidence Report issued by the Institute for Clinical and Economic Review (ICER) on its Midomafetamine...
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) reported audited financial results for its fiscal year ended March 31, 2024. The company does not have any...
The tech startup wants to address veteran suicide and mental health needs. Mental health technology firm INVI MindHealth secured $1.5 million in seed funding, the startup...
Canadian psychedelics firm MindBio Therapeutics Corp. (CSE: MBIO) on Friday released durability results from its Phase 2A trial for its patented take-home microdose version of lysergic...
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has signed a letter of intent to buy MedBright AI Investments Inc. in an all-stock deal. In addition to...
Privately owned psychedelic therapy company Mindbloom announced the positive findings of the largest peer-reviewed study regarding ketamine therapy and psychedelic medicine. The study, published in the Journal of...
Psychedelic clinical research firm Alira Health will collaborate with the Scottsdale Research Institute (SRI) to provide regulatory and clinical support to bring clinical research of psilocybin...
Relmada Therapeutics Inc. (Nasdaq: RLMD) announced the publication of “promising” REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical...
Atai’s proposal to purchase the company will serve as a stalking horse bid under the Sale and Investment Solicitation Process. IntelGenx Corp. (OTCQB: IGXT) (TSX: IGX)...